The protein encoded by this gene is a subunit of a heterodimer that, along with SUPT16H, forms chromatin transcriptional elongation factor FACT. FACT interacts specifically with histones H2A/H2B to effect nucleosome disassembly and transcription elongation. FACT and cisplatin-damaged DNA may be crucial to the anticancer mechanism of cisplatin. This encoded protein contains a high mobility group box which most likely constitutes the structure recognition element for cisplatin-modified DNA. This protein also functions as a co-activator of the transcriptional activator p63.
Structure specific recognition protein 1 has been shown to interact with NEK9. SSRP1 further interacts with transcriptional activator p63. SSRP1 enhances the activity of full-length p63, but it has no effect on the N-terminus-deleted p63 (DeltaN-p63) variant.
Kelley DE, Stokes DG, Perry RP (1999). "CHD1 interacts with SSRP1 and depends on both its chromodomain and its ATPase/helicase-like domain for proper association with chromatin.". Chromosoma108 (1): 10–25. doi:10.1007/s004120050347. PMID10199952.
Spencer JA, Baron MH, Olson EN (1999). "Cooperative transcriptional activation by serum response factor and the high mobility group protein SSRP1.". J. Biol. Chem.274 (22): 15686–93. doi:10.1074/jbc.274.22.15686. PMID10336466.
Orphanides G, Wu WH, Lane WS, Hampsey M, Reinberg D (1999). "The chromatin-specific transcription elongation factor FACT comprises human SPT16 and SSRP1 proteins.". Nature400 (6741): 284–8. doi:10.1038/22350. PMID10421373.
Wada T, Orphanides G, Hasegawa J, Kim DK, Shima D, Yamaguchi Y et al. (2000). "FACT relieves DSIF/NELF-mediated inhibition of transcriptional elongation and reveals functional differences between P-TEFb and TFIIH.". Mol. Cell5 (6): 1067–72. doi:10.1016/S1097-2765(00)80272-5. PMID10912001.
Keller DM, Zeng X, Wang Y, Zhang QH, Kapoor M, Shu H et al. (2001). "A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1.". Mol. Cell7 (2): 283–92. doi:10.1016/S1097-2765(01)00176-9. PMID11239457.
Yarnell AT, Oh S, Reinberg D, Lippard SJ (2001). "Interaction of FACT, SSRP1, and the high mobility group (HMG) domain of SSRP1 with DNA damaged by the anticancer drug cisplatin.". J. Biol. Chem.276 (28): 25736–41. doi:10.1074/jbc.M101208200. PMID11344167.
Santoro P, De Andrea M, Migliaretti G, Trapani C, Landolfo S, Gariglio M (2002). "High prevalence of autoantibodies against the nuclear high mobility group (HMG) protein SSRP1 in sera from patients with systemic lupus erythematosus, but not other rheumatic diseases.". J. Rheumatol.29 (1): 90–3. PMID11824977.
Keller DM, Lu H (2003). "p53 serine 392 phosphorylation increases after UV through induction of the assembly of the CK2.hSPT16.SSRP1 complex.". J. Biol. Chem.277 (51): 50206–13. doi:10.1074/jbc.M209820200. PMID12393879.